Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: J Clin Virol. 2017 Apr 7;91:73–78. doi: 10.1016/j.jcv.2017.04.003

Figure 1. Panel A. AR-MS-VL1 Flow at Zuckerberg San Francisco General Hospital (ZSFG), Sept – Nov, 2015.

Figure 1

Figure 1

1ARCHITECT® HIV Ag/AB Combo (AR) for screening, followed by Multispot HIV-1/HIV-2 Rapid Test (MS) confirmation, and Abbott RealTime HIV-1 assay (VL) as needed for resolution of discrepant results

Panel B. AR-MS-VL1 Flow at STOP Study2, 2010-2013

1ARCHITECT® HIV Ag/AB Combo (AR) for screening, followed by Multispot HIV-1/HIV-2 Rapid Test (MS) confirmation, and Abbott RealTime HIV-1 assay (VL) as needed for resolution of discrepant results

2CDC Screening Targeted Populations to Interrupt On-going Chains of HIV Transmission with Enhanced Partner Notification (STOP) Study for targeted testing of MSM; data from publicly funded testing sites in San Francisco